Efficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus Erythematosus
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Several clinical studies have shown that rituximab is safe and effective for the induction of
remission in moderate to severe systemic lupus erythematosus, and has been recommended by
several guidelines for the induction of remission in refractory lupus with important organ
involvement. However, there are few studies on the use of rituximab in the long-term
maintenance and remission of the disease. There is no recognized scheme for the dose,
interval and course of treatment of the drug. In this study, patients with moderate and
severe systemic lupus erythematosus who achieved remission after standardized treatment were
randomly divided into two groups at 1:1 and followed up every 3 months for 24 months. The
basic situation and disease activity score of each subject were recorded. The recurrence rate
of each observation group was calculated, the influencing factors of disease recurrence were
analyzed, and a more reasonable drug use scheme was explored.
Phase:
Phase 4
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University